Let me explain better, I am NOT castrate resistant. My only ADT was the four shots of Firmagon in early 2015. I expect to begin regular ADT soon, but am searching for a better approach. Tall Allen: many thanks as always, but as I read the NCTs they are for those CR?
Of the 15 listed trials for ARN-509, there are two for which I might qualify, one if there is metastasis, one if not.
NCT02489318,A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (TITAN), is a possibility if I qualify as metastatic–I will see about
doing a new scan.
NCT02811809, Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer, will only be available in Texas.(I think, I have written for confirmation), but has the advantage that both arms receive ARN-509.
For checkpoint blockers, there are five listed in a search using prostate immune checkpoint (any more words tends to give zero results), generally for more advanced disease than my case. I have written for more information on “A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers” and asking whether having the removed gland available counts as “biopsy-accessible” (I would think not.)
Post Edited (Cigafred) : 7/13/2016 8:09:16 AM (GMT-6)